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Abstract. Type 1 diabetes (T1D) is an autoimmune disease of the β-cells of the
pancreas. The nonobese diabetic (NOD) mouse is a commonly used animal model,
with roughly an 80% incidence rate of T1D among females. In 100% of NOD mice,
macrophages and T-cells invade the islets in a process called insulitis. It can be several
weeks between insulitis and T1D, and some mice do not progress at all. It is thought
that this delay is mediated by regulatory T-cells (Tregs) and that a gradual loss of effec-
tiveness in this population leads to T1D. However, this does not explain why some mice
progress and others do not. We propose a simple mathematical model of the interaction
between β-cells and the immune populations, including regulatory T-cells. We find that
individual mice may enter one of two stable steady states: a ‘mild’ insulitis state that
does not progress to T1D and a ‘severe’ insulitis state that does. We then run a sensitiv-
ity analysis to identify which parameters affect incidence of T1D versus those that affect
age of onset. We also test the model by simulating several experimental manipulations
found in the literature that modify insulitis severity and/or Treg activity. Notably, we
are able to match a reproduce a large number of phenomena using a relatively small
number of equations. We finish by proposing experiments that could help validate or
refine the model.
1. Introduction
1.1. Biological background. Type 1 diabetes (T1D) is an autoimmune disorder in which
T-cells invade the islets of langerhans within the pancreas and kill insulin producing β-
cells. The nonobese diabetic or NOD mouse is an inbred mouse strain that spontaneously
develops T1D. Among females, the age of onset is on average 12-16 weeks, with an incidence
of 60-80%. Prior to T1D onset, at 3-4 weeks of age, immune cells such as CD4 T-cells, CD8
T-cells, and macrophages invade the islets. This infiltration, called insulitis, gradually
becomes more severe, affecting more islets and penetrating more deeply (see Figure 1). It
is present in all NOD mice, even those that do not develop T1D.
NOD mice exhibit multiple immune problems. For an extensive review, see [5]. Here
we focus on a few key differences from the wild type, which may mimic the factors that
lead to genetic susceptibility in humans. First, there is a failure in central tolerance
as NOD mice do not effectively present peptides from the proinsulin gene in the thymus.
This leads to the generation of a population of proinsulin reactive lymphocytes, although
these T-cells typically have a low affinity for their target T-cell antigen. These T-cells are
the first detected in the pancreas during immunopathogenesis and eventually give way to
other more reactive T-cell clones. However, the anti-proinsulin response appears to be
required [11, 34]. In humans, T1D is associated with lower expression of insulin in the
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Figure 1. Progression of insulitis in the islets. Over time, immune cells
such as T-cells and macrophages infiltrate the islets, killing β-cells and
decresing insulin production.
thymus [16]. Second, NOD mice have a defect in the clearance of apoptotic cells.
Specifically, this is a defect in macrophages, an antigen nonspecific immune cell with a
large number of jobs, including the clearance of dead cells and the activation of T-cells.
The excess apoptotic cells can become necrotic and trigger an inflammatory response by
macrophages. This defect is particularly important at the time of weaning when the
pancreas undergoes structural changes and heightened apoptosis [30]. This apoptotic
wave and subsequent inflammation initiates an immune response, and T-cells start to
infiltrate the pancreas (see Table 1). Finally, NOD mice have a defect in the growth
and survival factor IL-2. Despite its role as a T-cell growth factor, deficiency in IL-
2 typically leads to uncontrolled growth of effector T-cells as IL-2 is required for the
proliferation and survival of Tregs. Tregs can control the development of T1D in the NOD
mouse for several months, and T1D is greatly accelerated in Treg-deficient NOD mice
[6, 8]. Human T1D patients have impaired IL-2 signaling via a defect in the high affinity
IL-2 receptor [16].
It is unclear what causes T-cells to escape the regulation of Tregs and destroy β-cells.
The simplest hypothesis is that the destruction of β-cells within the islets is ongoing,
but that T1D is not diagnosed until the β-cell mass reaches a critical level. However,
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Table 1. T1D progression in the NOD mouse
Time Event Source
9-15 days Apoptotic Wave [30]
18 days T1D in Treg deficient NOD mice [6]
3 weeks Initiation of Insulitis [12]
4-5 weeks Insulin-specific CD8s dominate [29]
4-5 weeks Rapid T1D after ablation of Tregs [8]
6 weeks Differential Prognosis with MRI [12]
6-8 weeks Decline in Treg effectiveness [28]
8 weeks IGRP-specific CD8s appear [29]
8-12 weeks β-cell mass starts to decline [2]
12-16 weeks Rapid loss of β-cell mass [2]
16 weeks Median T1D onset [4]
quantification of the β-cell mass shows that it does not start to decline until 8-12 weeks
of age [2], 6-10 weeks after the apoptotic wave [30]. Ablation of Tregs in 4-6-week old
mice leads to rapid T1D onset [8], indicating that Tregs are required to prevent disease
progression. This suggests that Tregs possibly lose effectiveness over time. This hypothesis
is supported by the work of Tritt et al. [28], who find that older mice have similar numbers
of Tregs, but they are less able to control T1D than those of young adult mice, and Pop
et al. [22], who find that Tregs from older mice have a loss of function in vitro. Another
possibility is that β-cells gradually lose function over time. It may be that the β-cells
degranulate, losing their ability to produce insulin, [1] or simply apoptose [14, 27] in
response to increased demands. Finally, the delay may be due to the time it takes for the
development of a population of T-cells capable of killing β-cells. In the early stages of
insulitis, the most important population of T-cells is CD4s, or helper T-cells, which can
activate other components of the immune sytem, but not directly kill target cells. Another
population of T-cells, CD8s or killer T-cells, is very efficient at killing target cells, but
require additional activation. In the early stages of T1D in NOD mice, the CD8 population
is generally insulin-specific with a low affinity. After several weeks, high affinity CD8s,
specific to islet-specific glucose-6-phosphate catalytic subunit related protein (IGRP), take
their place. The destruction of β-cells corresponds to the expansion of this population [4].
Almost all NOD mice develop insulitis, and yet many do not develop T1D. Trudeau et al.
[29] find signficant differences in the makeup of the CD8 T-cell population between those
that get T1D and those that do not. In particular, CD8 T-cells specific for the islet antigen
IGRP are at much higher levels in the ‘prediabetic’ mice, although they do not appear
until week 8 in either group [29]. Fu et al. [12] perform MRIs of mice at different ages and
find that the degree of inflammation is significantly greater in the mice destined for T1D.
At 6 weeks, inflammation of the pancreas is significantly correlated with the eventual
development of T1D. They also find that the mice with lower inflammation expressed
higher levels of CRIg, a marker of a class of regulatory macrophages. Taken together,
these studies suggest that the eventual fate of an individual mouse is predetermined at
the initiation of insulitis. The nature of the insulitis of each mouse should therefore fall
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into at least two classes, which can be distinguished by the presence of CRIg-expressing
macrophages. Islets with more severe inflammation have a greater level of β-cell turnover
and therefore a greater presentation of IGRP. This ultimately leads to a greater IGRP
CD8 response and T1D.
1.2. Prior modeling. As discussed above, the initiation of T1D requires a proinflam-
matory stimulus, which, in the NOD mouse, likely occurs during weaning. Nerup and
colleagues [21] propose a nonmathematical description of T1D initiation, the ‘Copen-
hagen Model’, which is not specific to NOD mice. The stimulating event, such as a virus,
causes minor β-cell destruction and, more importantly, releases β-cell antigens triggering
an immune cascade. De Blasio et al. [7] proposed a simple model of 4 ODEs (resting
and activated macrophages, β-cell antigen and T-cells) to reproduce this phenomenon.
The model is intentionally generic and does not describe any particular environmental
insult. They find that the activity of Macrophages is key and that the nature of the T-cell
response does not drive inflammation. Maree et al. [20] expanded upon this model and
incorporated the ideas of Trudeau [30]: that NOD mice have a reduced ability to clear
apoptotic β-cells that then become necrotic. They find that for NOD mice, the system
is bistable; the wave of apoptosis transfers the system from a resting ‘healthy’ state to a
‘disease’ state.
Regulatory T-cells play an important role of slowing the progression of T1D and other
autoimmune diseases. Alexander et al. [3] study a generic model of the Treg-controlled
autoimmune disease. They demonstrate that Tregs may not eliminate an autoimmune
response, but can reduce it to a subclinical level. Similarly, Magombdze et al. incorporate
Treg control into the framework of the Copenhagen/Maree models and find that Tregs
cannot eliminate the autoimmune response, but can reduce its intensity so that the β-cell
population is barely affected.
Leah Keshet and colleagues have investigated the dynamics of the CD8 population in
a series of papers. The time series of the IGRP CD8 population in [29] appears cyclical.
Mahaffy, Keshet et al. [19] model this phenomenon using multiple T-cell compartments:
‘activated’ T-cells can become either effectors and memory cells (which can later become
activated upon restimulation). Their model reproduces the observed cycle and the β-cells
die off step-wise during each cycle until none remain. Khadra, Keshet et al. [17] investigate
the competition between low-affinity and high-affinity CD8s. High-affinity CD8s kill β-
cells, releasing antigens and perpetuate the immune response, whereas low-affinity CD8s
simply crowd the environment. This leads, fairly robustly, to a bistable system that has a
‘healthy’ state with few high-affinity CD8s and a ‘diseased’ state with many.
1.3. Outline of our approach. We seek a simple model that
(1) has two possible outcomes, a ‘T1D’ state and an ‘insulitis but no T1D’ state;
(2) develops T1D predominantly within a narrow time window; and
(3) is initially under the control of a Treg population, which it subsequently escapes.
We propose a model of T1D development that proceeds in two stages. An ‘initiation’
phase corresponding to the development-driven apoptosis and a ‘progression’ phase de-
scribing the increase in the number and reactivity of the islet-specific CD8 population.
The initiation phase has two distinct outcomes corresponding to distinct stable equilibria:
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mild-insulitis, which does not lead to progression, and severe-insulitis, which does.
These two states are characterized by differences in the makeup of the macrophage pop-
ulation, the ratio of infiltrating Tregs to effector T-cells, and the cytokine milieu of the
islet. We show how various treatments can shift the system from the severe insulitis state
to the mild. The ‘progression’ phase is a feedforward model. Activated macrophages
stimulate the growth of the CD8 population, which in turn kill β-cells causing a rise in
blood glucose. Only in the severe insulitis state do the activated macrophages promote a
sufficient growth in CD8 cells to promote T1D development.
We then validate this model by simulating various treatments of NOD mice found
in the literature and comparing the results. To replicate incidence data, we must have
heterogeneity in the mouse population. We generate this heterogeneity by changing the
initial number of activated macrophages and the death rate due to CD8s, which we assume
are quite variable. The justification for this is that they are the result of complicated
processes (see [20] and [17], respectively) that can have multiple outcomes in otherwise
identical organisms. We add a small amount of noise to all other parameters. We then
perform a sensitivity analysis to investigate which parameters are key for the development
of T1D. Specifically, we are interested in those that lead to an acceleration or delay of
T1D versus those that change the incidence. Finally, we propose some further extensions
and some possible experiments to further validate the model.
2. The initiation model
2.1. Activation of macrophages. Macrophages are among the first cells to infiltrate
the islet in NOD mice [16], likely in response to an apoptotic wave of β-cell death during
weaning (the ‘apoptotic wave’, see [30]). As explored in [20], NOD macrophages are
inefficient at clearing these apoptotic cells, which leads to further inflammation and β-cell
death. Here, we shall assume that the apoptotic wave has just passed, resulting in an
initial excess of macrophages.
Tissue-resident macrophages are a type of innate immune cell, meaning non-antigen-
specific, with an incredibly wide array of potential behaviors. They phagocytose other
cells, act as antigen presenting cells (APCs) and control the behavior of neighboring cells,
both immune and nonimmune, via the release of cytokines. They are critical in the ini-
tiation and continuation of immune responses and yet they can also act as ‘custodians’,
clearing away debris from dead cells. These regulatory activities correlate with the expre-
sion of the receptor CRIg on a macrophages surface. CRIg expression is promoted by the
regulatory molecule IL-10 and inhibited by the inflammatory molecule IFN-γ as well as
other inflammatory molecules such as arachidonic acid [13]. Importantly, the expression
of CRIg by pancreatic macrophages is negatively correlated with the progression to T1D
[12]. Both IL-10 and IFN-γ are cytokines: diffusing, extracellular molecules used for
communication between cells, typically of the immune system.
We assume there are two classes of Macrophage: inflamatory macrophages (M∗), corre-
sponding to low CRIg expression, which can stimulate the activation and proliferation of
T-cells, and regulatory macrophages (M), corresponding to high CRIg expression which
act primarily as phagocytes. Macrophages can switch back and forth in response to ex-
ternal signals from cytokines. All macrophages enter the pancreas at a rate J in the
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regulatory class. They activate to become inflammatory at a basal rate a0, but their
activation rate can be greatly enhanced by IFN-γ. Likewise, inflammatory macrophages
deactivate at a basal rate b0, and their deactivation rate is enhanced by IL-10.
dM∗
dt
= aM − bM∗ − δM∗
dM
dt
= J − aM + bM∗ − δM
a = aγ
I2γ
k2γ + I
2
γ
+ a0
b = b10
I210
k210 + I
2
10
+ b0
IFN-γ is produced by TH1 effector CD4 T-cells (T ) in response to IL-12, a product of
inflammatory macrophages. We let T ∗ denote the population of effector T-cells expressing
IFN-γ. IL-10 is produced by CD4 Tregs (R). Pancreatic Tregs in NOD mice overexpress
IL-10, so we assume that the entire population expresses IL-10 without the need for further
stimulation.
dT ∗
dt
= c
I212
k212 + I
2
12
(T − T ∗)− eT ∗(1)
dIγ
dt
= αγT
∗ − ωγIγ(2)
dI12
dt
= α12M
∗ − ω12I12(3)
dI10
dt
= α10R− ω10I10,(4)
where c is the rate at which T-cells are activated by IL-12 and e is the rate at which they
revert to resting. Cytokine i is produced at a rate αi and decays at rate ωi. We assume that
all cytokine concentrations equilibriate rapidly. Therefore, we set (3)-(4) equal to zero,
and solve for the equilibrium concentrations. This yields the three-dimensional ODE:
dM∗
dt
= −δMM∗ +
(
aγF (νγT
∗) + a0
)
M − (b10F (ν10R) + b0)M∗
dM
dt
= J − δMM −
(
aγF (νγT
∗) + a0
)
M + (b10F (ν10R) + b0)M
∗
dT ∗
dt
= cF (ν12M
∗)(T − T ∗)− eT ∗
(5)
where
F (x) =
x2
x2 + 1
νi = αi/ωiki.
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2.2. Analysis of equilibria. The equilibria of (5) are given by
T ∗ = C(M∗eq)T =
cF (ν12M
∗
eq)
e+ cF (ν12M∗eq)
T
M =
J
δM
−M∗eq
M∗ = M∗eq
where M∗eq satisfies
M∗eq =
J
δD
A(M∗eq, T )
δD +B(R) +A(M∗eq, T )
A(M∗eq, T ) = aγF (νγTC(M
∗
eq) + a0
B(R) = b10F (ν10R) + b0.
(6)
(6) represents a fifth degree polynomial, whose coefficients alternate signs. Therefore we
expect it to have 1, 3, or 5 positive real roots. For any parameter choice, the number and
value of these equilibria will depend on the state variables T and R, whose dynamics are
discussed in the next section.
With our parameter values (see Table 2) there are either 1 or 3 solutions, depending
on the values of T and R. For fixed R and small values of T , as in Figure 2A, there is
only one solution with few inflammatory macrophages. This agrees with the observation
that CD4s are required for the initiation of T1D [5]. There is also only one solution
for large values of T , corresponding to large numbers of inflammatory macrophages. For
intermediate values of T , there is both the inflamed and noninflamed solutions, separated
by an unstable threshold solution.
A
R=0
R=3*10^6
R=1*10^7
0 2 4 6 8 10
0.0
0.2
0.4
0.6
0.8
1.0
T H107cellsL
M
eq*
H10
7 c
el
lsL
B
T=1*106
T=2*107
T=1*108
0.0 0.2 0.4 0.6 0.8 1.0
0.0
0.2
0.4
0.6
0.8
1.0
R H107cellsL
M
eq*
H10
7 c
el
lsL
Figure 2. Equilibria of (5) with the parameters in Table 3.2.
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Table 2. Parameter values used in the model
Parameter Description value
J Influx of macrophages into pancreas 1 *106cells
δ Turnover of macrophages in pancreas 1 days−1
a0 Basal macrophage activation rate of macrophages .05 days
−1
aγ Macrophage activation rate induced by IFN-γ 8 days
−1
b0 Basal macrophage deactivation rate .4 days
−1
b10 Macrophage deactivation rate induced by IL-10 8 days
−1
c CD4 activation rate by IL-12 8 days−1
e CD4 deactivation rate 5.5days−1
νγ Scaled IFN-γ affinity of macrophages 2δ/J
ν10 Scaled IL-10 affinity of macrophages δ/J
ν12 Scaled IL-12 affinity of CD4 T-cells δ/J
αT Influx of effectors into islets .7 *10
6cells
αR Influx of Tregs into islets .3 *10
6cells
γT Proliferation rate of effectors 2 days
−1
γR Proliferation rate of Tregs 2 days
−1
σT Max fraction of effectors in mitosis .4
σR Max fraction of Tregs in mitosis .8
δT1 Basal death rate of Tregs in pancreas .2 days
−1
δT2 Death rate of Tregs due to IL-2 deficiency .8 days
−1
kR Scaled affinity of Tregs for IL-2 5 δ/J
kT Scaled affinity of effectors for IL-2 20 δ/J
αC Production of CD8s .03
γC Division rate of CD8s .27
δC1 Death rate of CD8s .01
δC2 Autoregulation rate of CD8s 2.6*10
−6 cells−1days−1
kC Saturation constant for CD8 proliferation .75 J
η4 Rate of β-cell killing by CD4 .3
sT4 Saturation constant of CD4 killing 1
sR4 Control of Tregs over CD4 killing 30
η8 Per capita rate of beta cell killing by CD8 3.2 *10
6cells
γB Growth rate of beta cells .06
Ghb Glucose level for half maximal beta cell growth 161
δB Death rate of beta cells 1/60
R0 Average glucose production 864 mgdays
−1
EG0 Basal glucose decay rate 1.44 days
−1
SI Rate of insulin-mediated glucose uptake .72 days
−1/per µU
σI Max insulin production rate 43.2 µUdays
−1per mg
δI Insulin decay rate 432 days
−1
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2.3. Tregs and effectors compete in the islet. During the progession of T1D, T-cells
infiltrate the pancreatic islets. Cytotoxic CD8 T-cells directly kill β-cells, but the CD4
population also plays a role by maintaining an inflammatory environment that perpetuates
the immune response. The CD4 population, also called helper T-cells, is often divided into
two broad categories: effector T-cells and regulatory T-cells, which respectively promote
or obstruct immune responses. T1D does not develop in NOD mice in the absence of
CD4 effectors. With effectors present but not Tregs, the disease develops much faster,
indicating that they also play an important role [6].
Effectors and Tregs enter the islet at a rate of αT and αR, respectively. Although
there are other populations of antigen presenting cells in the pancreas, we assume that
T-cells are dependent upon interaction with macrophages in order to proliferate. This is
equivalent to assuming that other APC population numbers are correlated with those of
inflammatory macrophages. The maximum per-capita growth rate should therefore occur
when there are very few T-cells relative to macrophages as the competition for binding
space will be minimal. The decrease in proliferation rate as T-cell numbers increase has
been observed in vivo [26]. For simplicity, we model this process as a Michaelis-Menten rate
with the inflammatory macrophage acting analagously to an enzyme. We let σ denote the
maximum proportion of T-cells undergoing mitosis and γ denote the exponential growth
rate of those dividing cells. The maximum possible growth rate of the T-cell population
is therefore γσ.
The IL-2-BCL-2 pathway controls apoptosis of T-cells in the islets [26]. Secreted IL-2
promotes the expression of the antiapoptotic factor BCL-2 in T-cells. Tregs are dependent
upon effectors for IL-2, whereas effectors are self sufficient. NOD mice are deficient in IL-2,
leading to increased turnover in Tregs but not effectors [26]. Therefore, we assume that
T-cells die at a constant rate δT1 but that Tregs will die at an enhanced rate δT1 + δT2 in
the absence of IL-2. Effectors secrete IL-2 at a rate α2 and it is taken up by Tregs at a
rate ω2. In addition, we include an input u(t) representing IL-2 treatment.
dT
dt
= αT + γT
σTM
∗T
M∗ + σTT + σRR
− δT1T
dR
dt
= αR + γR
σRM
∗R
M∗ + σTT + σRR
−
(
δT1 + δT2
k
k + I2
)
R
dI2
dt
= α2T − δ2I2 − ω2I2R+ u(t)
Putting the cytokine concentration in steady state,
dT
dt
= αT + γT
σTM
∗T
M∗ + σTT + σRR
− δT1T
dR
dt
= αR + γR
σRM
∗R
M∗ + σTT + σRR
−
(
δT1 + δT2
kRR+ 1
Q(t) + kTT + kRR+ 1
)
R
(7)
where Q(t) = u(t)/kδ2 is the scaled IL-2 treatment, kT = α2/kδ2 the scaled IL-2 produc-
tion rate and kR = ω2/δ2 the scaled uptake by Tregs. Equation (7) and (5) together make
up the initiation model.
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2.4. Analysis of the initiation model. To simplify the analysis of this model, we
consider the case αT = αR = 0 with Q(t) = Q. The system (7) then becomes
0 = γT
σTM
∗
eqT
M∗eq + σTT + σRR
− δT1T
0 = γR
σRM
∗
eqR
M∗eq + σTT + σRR
−
(
δT1 + δT2
kRR+ 1
Q+ kTT + kRR+ 1
)
R
which has four solution branches: the trivial solution T0 = R0 = 0, a ‘T -only’ solution
with
T1 =
γTσT − δT1
σT δT1
Meq(8)
R1 = 0(9)
an ‘R-only’ solution satisfying
T2 = 0(10)
0 = γR
σRM
∗
eq
M∗eq + σRR2
−
(
δT1 + δT2
kRR2 + 1
Q+ kRR2 + 1
)
(11)
and a ‘coexistence’ solution satisfying
0 = γT
σTM
∗
eq
M∗eq + σTT3 + σRR3
− δT1(12)
0 = γR
σRM
∗
eq
M∗eq + σTT3 + σRR3
−
(
δT1 + δT2
kRR3 + 1
Q+ kTT3 + kRR3 + 1
)
(13)
Each of these solutions exist for αT ,αR > 0; however, only the coexistent solution is
guaranteed to remain positive. The other three solutions are positive if and only if they
are stable. Recalling that M∗eq represents the solution of a 5th degree polynomial whose
coefficients depend on T and R, we cannot directly solve this system. However, if we view
M∗eq as a parameter, we can implicitly solve for R, T and a parameter of our choice to
create bifurcation diagrams.
First we vary kT (Figure 3A) to simulate different levels of IL-2 production by NOD
mice. At the current parameter values (left dotted line), there are two stable equilibria:
severe (M∗1 ) and mild (M∗2 ) insulitis. As kT increases, the severe equilibrium disappears.
This is observed in [23], when a wild type IL-2 gene bred into the NOD mice greatly
reduces T1D.
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Next we increase Q (Figure 3B) to simulate exogenous IL-2 treatment. The effect is
similar to increasing kT , except that the lower solution branch undergous a transcritical
bifurcation (red region) and switches to the R-only equilibrium. The arrows indicate,
conceptually, the trajectory of the system during treatment. The trajectory starts on the
upper branch, but is forced down onto the lower one after the saddle-node bifurcation.
After treatment, the trajectory remains on the lower branch.
Finally, we vary σR and σT simultaneously while keeping them in the same proportion
(Figure 3C). This represents treatment with anti-CD3 (which actually decreases these
values to zero). The result is almost exactly the same as treatment with IL-2, with
the trajectory dropping down onto the lower branch after the saddle-node bifurcation.
Even though this branch is on the T -only equilibrium initially (blue region), it eventually
undergoes a transcritical bifurcation to arrive at the mild insulitis equilibrium.
2.5. Parameter estimation. The typical lifespan of a macrophage within the pancreas
is 10 days, so we let δ = .1 days−1[20]. The concentration of these cells in the inflamed
pancreas is 1∗107cell/ml, which we then take to be J/δ, the total number of macrophages
in our model at equilibrium [20]. The macrophage deactivation rate is b0 = .4 [20]. We
assume that αT +αR has a similiar magnitude to the macrophage influx J . From [26], we
see that Tregs initially account for 30% of the CD4 population. Therefore, we let αR = .3J
and αT = .7J . From [32], we note that IL-12 triggers IFN-γ after roughly 8 hours, and so
we assume that aγ = c = 8 days
−1. Also from [32], the half life of the expression of IFN-γ
is about 3 hrs, so e = 5.5 days−1.
Initially, we let ν12 = ν10 = νγ = δ/J . This is so that the argument passed to F
would be close to 1, and so its sigmoidal behavior would be relevant. We find that with
these parameters, the basin of attraction of the severe insulitis state is so small that the
equilibrium cannot be reached from reasonable initial conditions. Doubling the value of
νγ resolves this.
We let γT = γR = 2, which corresponds to a doubling time of 8 hours. We can directly
observe σT ≈ .4 and σR ≈ .8 from the proliferation data in [26]. We also note that, at
equilibrium, roughly 10% of effectors are dividing. Assuming that the proliferation rate
matches the death rate at this point, we find that δT1 = .2. To fit the final parameters, we
note that at equilibrium, roughly 20% of Tregs are dividing and that the ratio of Tregs to
effectors is about 9 to 1 [26]. Taken together, this allows us to fit the parameters δT2 = .8,
kT = 5δ/J and kR = 20δ/J .
3. The progression model
3.1. CD8 T-cells. NOD mice have multiple lineages of islet specific T-cells, however,
we focus on the high affinity IGRP/NRP-specific subset. We assume that these cells are
generated at a low frequency due to control by central tolerance, but that they proliferate
when the islet antigen IGRP is presented with costimulation in either the Pancreatic
Lymph Node or the islets themselves. Following [19], we use both a linear death term,
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representing normal turnover, and quadratic death term, representing autoregulation by
the CD8 population.
(14)
dC
dt
= αC +
(
γC
M∗
M∗ + kC
− δC1
)
C − δC2C2
To parameterize this system we use the data for NRP-A7 CD8 T-cells in [4]. Assuming
that αC is small and that M
∗ is constant from week 5 onwards. Then (14) becomes
dC
dt
≈ AiC − δC2C2(15)
Ai = γC
M∗i
M∗i + kC
− δC1(16)
Where Ai represents the exponential growth rate of CD8 population when M
∗ = M∗i .
From the time series data, we can estimate that δC2 = 2.6∗10−6cells−1days−1and A2 = .13
days−1. From [29], we know that there are roughly 8 times as many NRP specific CD8
in mice that get T1D versus those that do not. This implies that A2 ≈ 8 ∗ A1. Taken
together, these two relations allow us to estimate the values of γC = .27 days
−1and
kC = .75J . Finally, αC remains as an important parameter controlling the timing of the
expansion of the CD8 T-cells. We adjust αC , after assigning all other parameters, so that
the median onset of T1D occurs at 16 weeks. This gives αC = .03 cells per day.
3.2. Metabolic subsystem. In most experiments, a T1D diagnosis corresponds to a
blood glucose level 250mg/dl (normal is 100mg/dl). Glucose controls both the proliferation
rate and insulin production of beta cells. The produced insulin, in turn, stimulates the
uptake of blood glucose. Topp et al. [27] modeled the insulin-glucose system with the
following differential equations.
dG
dt
= R0 − (EG0 − SII)G(17)
dI
dt
= σIB
G2
G2 +G2I
− δII(18)
As, δI  1, we assume that the insulin level I is in equilibrium.
dG
dt
= R0 −
(
EG0 +
SIσI
δI
B
G2
G2 +G2i
)
G(19)
To account for the increase in proliferation, we follow the work of [14] who created a highly
detailed model of beta cell function. We simplify their model as
dB
dt
=
(
γB
G2
G2 +G2hb
− δB
)
B.(20)
To parameterize this model we note the following. First, we observe from [24] that the
number of proliferating cells reaches roughly 3%. This corresponds to a max growth rate
γB = .06. The lifespan of a typical beta cell is 60 days [14] so δB = 1/60. The resting
population of β-cells in the absence of an immune response is B∗ = 300, allowing us to
solve for Ghb = 161mg/dl.
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In [15], untreated mice experience an increase in blood glucose from 300mg/dl to
500mg/dl in the first 2 weeks after onset. This corresponds to a decrease in β-cell mass
from 24 to 4.32 in our model, a loss of roughly 12% daily. To offset compensatory growth,
the immune response must remove about 16% of β-cells daily. In treated mice, on the
other hand, glucose levels drop to about 200mg/dl, which is still twice the baseline level.
In our model, we can only account for this by a continued immune destruction of about
2% of immune cells daily. This means that the strength of the immune response is roughly
8 times less after treatment than before. Interestingly, this prediction corresponds closely
to the ratio of NRP-reactive cells found in [29] between mice that get T1D and those that
do not. Taken together, we conclude that we can model β-cell death due to CD8s as mass
action with a constant of η8 = 3.2 ∗ 10−6 cells−1days−1.
CD4s can also kill β-cells, although this primarily happens in the absence of Tregs. We
include a killing term due to CD4s, which only becomes relevant to model behavior if
Tregs are either absent [6] or removed [8]. Our final β-cell equation is
dB
dt
=
(
γB
G2
G2 +G2hb
− δB − η8C − η4 (sT4T
∗)2
1 + (sT4T ∗)2 + (sR4R)2
)
B.(21)
4. Simulating treatments
In the next section, we simulate the treatments described in various papers. Table 3
summarizes the nature and duration of these treatments. Here we descibe the implemen-
tation of IFN-α treatment, anti-CD3 antibodies (aCD3 treatment), anti-PDL1 antibodies
(aPDL1 treatment), Treg treatment, and IL-2 treatment.
Table 3. Summary of Treatments
Treatment Change Timeframe
IFN-α Treatment Day 63-77 Set γC = ν12 = 0
Boost of Tregs Day 77-78 Increase αT by 15δ/J
anti-CD3 Treatment Day 35-49 Set σT = σR = δT2 = 0 and δT1 = 1
anti-PDL1 Treatment Day 119-133 Set γC = γT and ν12 = 20δ/J
IL-2 treatment Every two days Pulse Q with Q0 = 500 and δQ = 1days
−1
According to Filippi et al. [10], treatment with IFN-α boosts PD-L1 expression. PD-
L1 is a negative costimulatory molecule, so it impairs the ability of APCs to activate
T-cells. We therefore set ν12 = 0 so CD4s produce no IFN-γ, and γC = 0 so CD8s do not
proliferate [10]. Treatment with Tregs is relatively straightforward, directly increasing the
R population, which we implement by changing αR.
Fife et al. [9] treat with aPDL1, which we assume should have the opposite effect to
IFN-α treatment. We therefore increase ν12 by a factor of 10 and set γC equal to γT ,
which is the maximum growth rate of T-cells. Anti-CD3 interferes with the interaction
between T-cells and APCs. Thus, we let σT = σR = 0 to indicate that no division takes
place. We also set δT2 = 0 and δT1 = .1, which is equivalent to the assumption that both
effectors and Tregs die at the IL-2 deprived death rate of δT1 + δT2 as there is no source
of IL-2.
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Finally, to simulate IL-2 treatment we assume that Q obeys
Q = Q0
∑
ti
e(ti−t)δQH(ti − t)(22)
H(t) =
{
t t > 0
0 else
(23)
where the tis are spaced every 2 days for the duration of the treatment. This represents
pulses of Q0 that decay at a rate of δQ per day. This matches the treatment described in
[26].
5. Results
5.1. Magnitude of initial inflammation determines
T1D prognosis. As demonstrated in section 2.4, the intiation model (5) and (7) has
two stable equilibria, representing insulitis of different severities. By changing the initial
conditions, we can shift the long term behavior of the system from mild to severe insulitis
and the outcome from nondiabetic to diabetic. Specifically, we hold all initial conditions
constant with the exception of activated macrophages. We start each simulation at t0 = 14
days, during the apoptotic wave. The initial number of activated macrophages, M∗(t0),
will change depending on severity of the wave, which could vary between mice. Figure
4 shows time series for M∗(t0) = 1.6 ∗ 107cells (Figure 4A,B) and M∗(t0) = 8 ∗ 106cells
(Figure 4C,D). When M∗(t0) is high, the CD4 and macrophage populations equilibriate
relatively rapidly to the severe insulitis state (Figure 4A), eventually leading to T1D
onset (Glucose>250mg/dl) at 16 weeks (Figure 4C). When M∗(t0) is low, the CD4 and
macrophage populations equilibriate to the mild insulitis state (Figure 4C), and T1D does
not develop (Figure 4D).
5.2. Simulation of mouse populations. One of the main goals of this study is to
model the incidence of T1D in NOD mice under various treatments. Not all NOD mice
develop T1D, and the age of onset can vary among those that do. As our ODE model is
deterministic, we represent the differences between individuals via parameter values and
initial conditions. To simulate experiments with groups of N mice, we make N parameter
sets, sampling each parameter from a different distribution, described below. We then
replicate those parameter sets and initial conditions for each treatment, so differences
between treatments are never due to stochasticity. We start each simulation at the time of
the initial inflammation (t0 = 14 days). Therefore, we assume that the number of activated
macrophages will initially be elevated in each mouse, as our model does not include the
initiating event. The initial macrophage population could be different for each mouse due
to diet or differences in development. We draw this value from the normal distribution
(1.2 + N (.4, 1)) ∗ 107cells. Likewise, the value η8 is dependent on the affinity of CD8s
for β-cells and is therefore the outcome of a complicated process of gene rearrangement,
thymic selection, and the population dynamics of competing CD8 clones. Where specified,
we generate this value from the log-normal distribution 3.2 ∗ 10−1310N (0,1/9)days−1. We
generate all other parameters by sampling from a log-normal distribution with the means
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Figure 4. Time series with M∗(t0) = 1.6 ∗ 107cells (A,B) or M∗(t0) = 8 ∗
106cells (C,D). Panels A and C show the CD4 and macrophage populations.
Panels B and D show the CD8 population (black), β-cells (blue), blood
glucose (solid red), and the glucose threshold for T1D (250mg/dl, dotted
red).
given by the base parameters and the standard deviations as 1% of those means. When
we show the time series from an individual mouse, we use the parameters in Table 2.
5.3. Treatment with IL-2 increases Treg:Teff ratio
and prevents T1D. Several groups [15, 26] find that treatment with exogenous IL-2 can
restore the Treg population and prevent the development of T1D. We treat groups of 100
mice with 1, 5, or 11 weeks of IL-2 pulses (of 500 every 2 days). Treatment for 1 week
causes a transient but significicant drop in the CD4 population and a corresponding rise in
the Treg population (Figure 5A). This results in a very small delay in T1D, but no change
in incidence. Treatment for 5 weeks, on the other hand, leads to a permanent decrease
in the CD4 and inflammatory macrophage population and a permanent increase in the
Treg population. This leads to a very large decrease in incidence (Figure 6). Treatment
for 11 weeks has little marginal benefit as compared to 5 weeks. In both of these latter
16
cases, insulitis is greatly reduced, but remains perpetually. The lower level of insulitis
is insufficient, in most cases, to stimulate the growth of a killer CD8, and so T1D never
occurs.
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Figure 5. Simulation of IL-2 treatments of different lengths. Using the
baseline parameters, we simulated treatment with IL-2 for 0 (Panel A), 1
(Panel B), 5 (C), or 11(D) weeks. Each panel shows the time course of the
inflammatory macrophages (M∗), resting macrophages(M), effector CD4s
(T ), and Tregs (R). The dosage is Q = 500.
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5.4. CD3 induced tolerance requires continued activity
of PD-L1. Fife et al. [9] demonstrate that early treatment with an aCD3 prevents T1D.
CD3 is a surface protein on T-cells that helps them bind to antigen presenting cells. We
can represent CD3 treatment by setting σT = σR = 0 to indicate that no proliferation
takes place. We further modify the death rates of both effectors and Tregs to be δT1 +δT2,
indicating that they receive no survival signals from the IL-2-BCL pathway. Fife’s group
also treats some mice with a PD-L1 antibody. PD-L1 acts as a negative regulator of T-
cells. We represent PD-L1 treatment by increasing ν12 10-fold, corresponding to a decrease
in the activation threshold of CD4 T-cells. This change means that CD4 T-cells require
10 times less IL-12 to activate and start to produce IFN-γ. We also assume that more
PD-L1 dramatically increases the division rate of CD8 T-cells to the maximum rate of
T-cell division γT .
We follow the same protocol as Fife, treating with aCD3 at 5 weeks and aPD-L1 at 17
weeks, with both treatments lasting for 2 weeks. Our results (Figure 7) match the key
features of the experiment. With aCD3 treatment, aPD-L1 accelerates T1D among NOD
mice and leads to a much higher incidence. Mice that received aCD3 alone did not develop
any T1D, whereas 100% of those that also received aPD-L1 rapidly developed T1D shortly
after the latter treatment.
5.5. Synergy between IFN-α and Tregs. Filippi et al. [10] study the role of viruses in
the regulation of T1D in NOD mice. They find that the virus LCMV transiently increases
PD-L1 expression. In addition, they hypothesize that the Treg population generated dur-
ing the immune response may explain the decreased T1D among LCMV treated mice. To
test this hypothesis, they treat mice with IFN-α, which can also increase PD-L1 expression
and transfer Tregs from mice previously exposed to LCMV.
We represent the boost in PD-L1 by setting ν12 = 0, meaning that APCs cannot activate
CD4 T-cells to produce IFN-γ, and γC = 0, meaning that CD8 T-cells cannot divide.
This is esentially the inverse of how we modeled the aPD-L1 treatment. We represent the
injection of T-cells by increasing αR for the duration of the treatment.
Like Fillipi, we find synergy between the two treatments (Figure 8). The administration
of IFN-α by itself does not change the incidence of T1D, but it does delay the age of
onset. The administration of Tregs by themselves does not change the age of onset, but
does decrease incidence. The combination of both treatments decreases incidence by more
than the sum of the individual treatments. All of these observations replicate Fillipi’s
findings. In this experiment, we used a smaller range of η8 to bring it in line with the
other parameters. Without this change, the variance is so large that it obscures the
synergy.
5.6. CD4 and macrophage parameters affect incidence while
CD8 parameters affect age of onset. To determine which parameters contribute to
incidence and which to age of onset, we ran a sensitivity analysis for each parameter. First
we generate 100 pairs of values of η8 and M
∗(t0), our two key parameters. Then we vary
each parameter, one at a time, from 50% to 200% of its baseline value, equally spaced
on a log scale, with every other parameter fixed at its baseline. For each value of the
current parameter, we simulate the system using each of the 100 parameters pairs for η8
and M∗(t0). We record if and when T1D develops in each simulation.
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Figure 6. Incidence of T1D with IL-2 treatment for 0, 1, 5, or 11 weeks.
Figures 9, 10, and 11 summarize the results of the sensitivity analysis. In each panel, we
vary a different parameter. The blue line shows the incidence, while the red and grey lines
show the median and deciles, respectively, of the age of onset. Figure 9 shows parameters
that primarily affect age of onset, Figure 10 shows those that primarily affect incidence,
and Figure 11 shows those with strongs effects on both. In general, the parameters that
describe CD4 and macrophage behavior affect only incidence and those that describe CD8
behavior affect only the age of onset. We summarize this pattern in Figure 12 that shows
the entire model, with each arrow color-coded and scaled according to its significance.
Bolder arrows have greater significance, red arrows affect primarily age of onset, blue
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Figure 7. Simulation of treatment of NOD mice with aCD3 and aPDL1.
We generated 100 different parameter sets (‘mice’) and simulated each T1D
progression under four different simluated treatments. Mice received no
treatment, aCD3 at 5 weeks of age, aPDL1 at 17 weeks, or both treatments.
This is a replication of experiment from [9].
affect incidence, and purple arrows affect both. Greyed-out arrows have little affect on
the model and are confined to the metabolic processes in the model.
6. Discussion
In this paper, we present a mathematical model of Type 1 diabetes (T1D) in the NOD
mouse. We propose that the intensity of the apoptotic wave controls the eventual develop-
ment of T1D. We further propose that the long delay between this initial inflammation and
the destruction of the islets is due to the growth and maturation of the CD8 population.
Therefore, the model has two components: an ‘initiation’ component that consists of equa-
tions governing the interaction of CD4s and macrophage populations, and a ‘progression’
component that describes the growth of CD8s, their killing of β-cells, and the eventual
rise in blood glucose. The initiation component has two possible outcomes, defined by its
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Figure 8. Simulation of treatment of NOD mice with IFN-α and Tregs.
We generated 100 different parameter sets (‘mice’) and simulated each T1D
progression under four different simluated treatments. Mice received no
treatment, IFN-α at 9 weeks of age, Tregs at 11 weeks or both treatments.
This is a replication of experiment from [10].
stable equilibria, only one of which leads to T1D. These equilibria are distinguished by
the relative activity of Tregs, effectors, and activated macrophages and their associated
cytokines: IL-10, IFN-γ and IL-12.
21
Macrophage Death Rate
60
80
10
0
D
is
ea
se
 O
ns
et
 (D
ay
s)
0
20
60
10
0
To
ta
l P
e
n
e
tra
n
ce
(%
)
0.05 0.10 0.15 0.20
IL−2 use by Teff
60
80
10
0
D
is
ea
se
 O
ns
et
 (D
ay
s)
0
20
60
10
0
To
ta
l P
e
n
e
tra
n
ce
(%
)
4 6 8 10
IL2 use by Treg
60
80
10
0
D
is
ea
se
 O
ns
et
 (D
ay
s)
0
20
60
10
0
To
ta
l P
e
n
e
tra
n
ce
(%
)
10 15 20 25 30 35
Division rate of CD8
60
80
10
0
D
is
ea
se
 O
ns
et
 (D
ay
s)
0
20
60
10
0
To
ta
l P
e
n
e
tra
n
ce
(%
)
0.2 0.3 0.4 0.5
Saturation constant for CD8 proliferation
60
80
10
0
D
is
ea
se
 O
ns
et
 (D
ay
s)
0
20
60
10
0
To
ta
l P
e
n
e
tra
n
ce
(%
)
0.4 0.6 0.8 1.0 1.2
Production of Macs
60
80
10
0
D
is
ea
se
 O
ns
et
 (D
ay
s)
0
20
60
10
0
To
ta
l P
e
n
e
tra
n
ce
(%
)
0.05 0.10 0.15 0.20
Figure 9. Sensitivity analysis of full model. Parameters that primarily
affect age of onset. We vary an individual parameter from 50% to 200%
of its baseline value. We hold each other parameter constant except for
the killing rate of CD8 η8 and the initial number of activated macrophages
M∗(t0). The blue line shows the percentage of diabetic mice, by the end
of 50 weeks, in the sample. The red and grey lines show the median and
deciles, respectively, of the age of onset.
Our model reproduces the results of several experiments on NOD mice: aCD3 treatment,
aPDL1 treatment, IL-2 treatment, IFN-α treatment, and Treg treatment. All of these
treatments amount to shifting the trajectory from the basin of attraction of the severe-
insulitis state to that of the mild insulitis state. A treatment that does not cause a
transition can still cause a delay in insulitis. For example, IFN-α treatment alone does
not decrease incidence but does delay T1D due to downstream effects that interfere with
the CD8 population. When combined with adoptive transfer of Tregs, it does significantly
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Figure 10. Sensitivity analysis of full model. Parameters that primarily
affect incidnece. We vary an individual parameter from 50% to 200% of its
baseline value. For each other parameter, we randomly sample 100 times
from a normal distribution centered on the baseline value and run a seperate
simulation for each parameter set. The blue line shows the percentage of
diabetic mice, by the end of 50 weeks, in the sample. The red and grey
lines show the median and deciles, respectively, of the age of onset.
decrease incidence. According to our model, each treatment by itself is insufficient to make
the transition, and so the system returns to the severe-insulitis state once treatment is
over. Conversely, treatment with aPDL1 can shift the system from mild to severe arthritis.
We show that aCD3 treatment followed by aPDL1 shifts the system from severe to mild
and back to severe again. The equivalence between all of these treatments suggests that
the system is ‘memoryless’. A mouse that has been cured with aCD3 should be similar to
one cured via the transfer of Tregs or IFN-α. Fife et al. [9] found similarities between aCD3
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Figure 11. Sensitivity analysis of full model. Parameters that affect in-
cidence and age of onset. We vary an individual parameter from 50% to
200% of its baseline value. For each other parameter, we randomly sample
100 times from a normal distribution centered on the baseline value and
run a seperate simulation for each parameter set. The blue line shows the
percentage of diabetic mice, by the end of 50 weeks, in the sample. The
red and grey lines show the median and deciles, respectively, of the age of
onset.
treated mice and those that received insulin coupled splenocytes that tolerized them to
the peptide. Table 3.4 summarizes the experimental results that our model can reproduce.
In our model, Tregs play two separate roles. First, Tregs prevent the killing of β-cells
by CD4 T-cells. This is an assumption of the model given that Tregs have been observed
to control the extent of infiltration in the islet [6, 8]. Second, Tregs can control the inflam-
matory state of macrophages and other APCs which in turn prevents the development
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Figure 12. Schematic diagram summarizing the model in this paper. Ar-
rows are colored according to whether they affect incidence/penetrance
(blue), age of onset (red), or both (purple). The strength of the effect is
denoted by the arrow thickness. Arrows in dark cyan had negligible effect.
of a CD8 response. Due to IL-2 deficiency in NOD mice, Tregs are at a competitive
disadvantage in the islets, favoring a proinflammatory environment. In our model, this
proinflammatory envinronment is manifested in the severe insulitis equilibrium. We find
that a moderate increase in IL-2 production can eliminate this equilibrium. Treatment
with exogenous IL-2 does not eliminate this equilibrium in the long term, but can shift
the system to the mild equilibrium as the other treatments do.
It has been suggested that the Treg population loses either effectiveness [28] or popu-
lation size [26] over time. Lack of IL-2 uptake by Tregs decreases BCL-2 expression and
thus survival. Therefore, the IL-2 deficiency lowers the Treg:effector ratio in NOD islets
relative to the spleen and lymph nodes and relative to wild type islets. However, this ratio
does not decline as the mouse ages. Bleyer et al. find that it stays constant until disease
onset, when it rises slightly [15]. In our model, the Treg:effector ratio stays constant over
the progression of T1D and is not significantly different between mice that develop T1D
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Table 4. Key behaviors this model can reproduce
Phenomenom Source Outcome
T1D at 16 weeks [2] Fitted
T1D in 80% of females [5] Fitted
T1D rapid without Tregs [6] and [8]
Protection from T1D with enhanced IL-2 production [23]
Protection from T1D with exogenous IL-2 [23]
Protection from T1D with anti-CD3 treatment [9]
Protection from T1D with Treg treatment [10]
Delay of T1D with IFN-α treatment [10]
Synergy between Treg and IFN-α treatments [10]
NOD8.3 have faster onset, same incidence [31]
IGRP-specific CD8 predict outcome [29]
Inflammation predicts T1D months in advance [12]
and those that do not. This is not to say that the Treg population does not decline in
NOD mice, but we need not assume it to reproduce the known phenomena. The presence
of T1D-resistant mice, either naturally or following treatment by IL-2, IFN-α, or aCD3,
suggests ongoing regulation of the insulitic legion by Tregs. If the Tregs were to intrinsi-
cally decline, we would expect all of these mice to also develop T1D. Although this process
may happen on a timescale longer than current experiments, it cannot be the driving force
behind onset of T1D.
CD8 killer T-cells drive the eventual decline of the β-cell population. Although, in this
model, CD4 T-cells also possess the capacity to destroy β-cells, they do not do so in the
presence of Tregs (as in [8]). The CD8 population in our model represents the population
of high affinity CD8 specific to IGRP. Trudeau et al. [29] use the size of this population to
predict T1D outcome, and Amrani et al. [4] show that an increase in the average affinity
of the CD8 population for IGRP correspond with disease onset. To eliminate the β-cell
population, the CD8 population must kill them faster than the β-cells can divide. We
estimate that at the time of disease onset, CD8 T-cells kill β-cells at a rate of roughly 16%
a day, which is almost 3 times as fast as β-cells have been observed to divide. Therefore,
a slight decrease in CD8 number or effectiveness is unlikely to prevent T1D development,
although it can slow it. We find that CD8 related parameters primarily contribute to the
age of onset instead of T1D incidence. In agreement with this, TCR8.3 NOD transgenic
mice that produce only high-affinity IGRP-specific CD8 T-cells have a more rapid onset,
but similiar incidence to NOD mice [31].
In this model, the treatment of the CD8 population is extremely simple. We only
track a single population that grows from a very small number of precursors. In NOD
mice, the CD8 population transitions from insulin specific to IGRP specific [4]. An initial
response to insulin is required for T1D progression [18], but it is unclear whether this is
due specifically to the activity of CD8s. It is plausible that initial low levels of β-cell death
due to insulin-specific CD8s releases IGRP, which is then presented on APC triggering
the switch in autoimmunity. It is also plausible that the CD8-mediated death is necessary
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to maintain the ‘severe-insulitis’ state that leads to T1D in this model. One possible
experiment to elucidate the role of CD8s would be to create a transgenic line of mice on
the NOD background whose CD8s lack the ability to kill β-cells. According to our simple
model of CD8s, they should still develop an IGRP-specific population in the same time
frame. If these NOD mice continue to produce primarily insulin-specific CD8s, that will
imply that CD8-related pathology drives the progression of their own β-cell affinity.
Another simplifying assumption of our model is that the β-cell population responds
only to glucose levels and only homeostatically. In fact, β-cells divide in response to islet
inflammation [25]. We have ignored this phenomenon, reasoning that the immune response
results in a net decrease in β-cells. In addition, β-cells can decompensate [25] when under
high demand, producing less insulin per cell. This is due in part to the degranulation
of β-cells during T1D progression [1]. Including any of these phenomena will change the
parameter estimates for the immune-mediated killing of β-cells. More importantly, it
could alter some of the conclusions of how we expect the β-cell population to respond
to treatment. For example, the inclusion of degranulated β-cells could allow for a rapid
rebound after IL-2 treatment in new onset mice, as in [15], which cannot be reproduced
by the one-compartment β-cell model we use.
In treating T1D in both NOD mice and humans, there are two main strategies. Admin-
istration of anti-inflammatories, such as anti-CD3, Vitamin D or omega-3s [16] can reduce
insulitis and hopefully prevent the development of an autoimmune destruction. Antigen
specific tolerance, such as with oral administration of insulin, aims to delete the autore-
active T-cell clones directly [16, 33]. Only the former have had successful trials among
humans, but the latter represent a more specific treatment.
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